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Abstract  
Objective:  Uterine myoma, which arises from 
the myometrium of uterus, is among the most 
common benign tumors of women. Generally, it 
has an asymptomatic character, however, in 
symptomatic cases, it presents with abnormal 
uterine bleeding. The objective of this study is to 
determine whether preoperative diagnostic 
curettage is essential or not by comparing the 
preoperative and postoperative endometriums of 
patients that underwent surgery with uterine 
myoma diagnosis.  
Material and Method: In this study,260 patients 
that received surgery with uterine myoma 
diagnosis in the Gynecology and Obstetrics 
Department of Taksim Education and Research 
Hospital in Istanbul  between January 2007 and 
January 2010, were included. The 
histopathologic analysis of specimens  obtained 
by preoperative curettage and hysterectomy, 
was carried out in a retrospective fashion.  
Results: The mean age of patients was 48.3 ± 
7.5 years. The distribution of preoperative 
curettage specimens with regard to endometrial 
status was as follows: phase compatible 
endometrium in 156 (60%), endometrial polyp in 
74 (28.5%), atrophic endometrium in 20 (7.7%), 
and endometrial hyperplasia in 10 patients 
(3.8%). Among the phase compatible 
endometriums, 85 patients (54.5%) had 
proliferative endometrium, 39 patients (25%) 
had late secretory phase endometrium, and 32 
patients (20.5%) had early secretory phase 
endometrium. The distribution of postoperative 
hysterectomy specimens with regard to 
endometrial status was as follows: Phase 
compatible endometrium in 160 patients 
(61.5%), endometrial polyp in 61 patients 
(22.5%), endometrial hyperplasia in 14 patients 
(5.4%), and atrophic endometrium in 25 patients 
(9.6%). Among the phase compatible 
endometriums; 96 patients (60%) had 
proliferative endometrium, 44 patients (27.5%) 
had late secretory endometrium, and 20 patients 
(12.5%) had early secretory endometrium.   
Conclusion: No difference was observed 
between the histopathologic results of diagnostic 
curettage and hysterectomy relative to 
malignancy or a pathology that would change 
the surgery plan. The result is very important 
because it shows that performing curettage 
before myoma surgery is not an essential 
procedure. In this study, since endometrial 
cancer may not have been detected due to 
limited number of patients, further studies 
including higher number of patients are required 
to confirm our results.  
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Introduction 
Uterine myoma is the proliferation of 
smooth muscle cells in myometrium 
which is known to be the most common 
pelvic tumor seen in women above 35 
years of age.1,2 The yearly incidence of 
uterine myoma (also called as 
fibromyoma, fibroma, fibroid, 
leiomyoma, myoma, and 
leiomyofibroma) is 12.8/1000 among 
women aged 25-44 years.3 However, it 
is not easy to determine the actual 
incidence of uterine myoma cases 
because of their generally asymptomatic 
course. Some studies report the myoma 
incidence among women as 50%.4 
When the entire hysterectomy 
specimens are included in this 
evaluation, this rate rises to 77%.5 Major 
risk factors of myoma development are 
early menarche, low parity, childbirth at 
young age, infertility, and starting oral 
contraceptives early. Many studies have 
shown that estrogen has a role in 
leiomyoma growth.6 In leiomyomas, the 
number of estrogen receptors and the 
expression of genes involved in the 
production of estrogen regulators such 
as connexin 43 gap-junction protein, 
Type I and III collagens, insulin-like 
growth factor-1, and parathyroid 
hormone-like peptide are observed to 
increase.7-11 Moreover, P450 enzyme 
system contributes to the growth of 
leiomyomas and estrogen elevates the 
mitogenic activity.12,13 Although uterine 
myomas develop under the influence of 
estrogen, the association between 
myoma and endometrial hyperplasia or 
endometrial carcinoma is not high. 
However, many gynecologists employ 
preoperative endometrial biopsy on a 
routine basis in cases diagnosed with 
uterine myoma and scheduled for 
hysterectomy in order to detect an 
endometrial hyperplasia or an 
endometrial adenocarcinoma 
beforehand.6,14  In our study, we aimed 
to determine whether preoperative 
diagnostic curettage is essential by 
comparing the histopathologic findings 
obtained before and after hysterectomy 
in patients diagnosed with uterine 
myoma.   
Material and Method 
In this study, 260 patients who 
presented to the Gynecology and 
Obstetrics Department of Taksim 
Education and Research Hospital ın 
Istanbul between January 2007 and 
January 2010, and received 
preoperative diagnostic curettage before 
undergoing surgery with diagnosis of 
uterine myoma, were included. The 
characteristics of the patients such as 
age, presenting symptoms, pre- and 
post-menopausal state, and the 
histopathologic findings of preoperative 
endometrial curettage and hysterectomy 
were retrospectively evaluated. In our 
department, the routine diagnostic 
curettage procedure includes dilatation 
of cervix with a Hegar dilator, ensued by 
application of curettage with a sharp 
curette after which obtained specimens 
are sent for histopathologic analysis. In 
cases where we fail to achieve dilatation 
by local anesthesia, general anesthesia 
is applied within operating room 
conditions. Patients receive 
hysterectomy after the curettage and the 
acquired hysterectomy specimen is 
prepared by paraffin method for 
macroscopic and microscopic 
histopathologic examination. In this 
study, we preferred to use descriptive 
statistics for the evaluation of study 
data. 
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Results 
The mean age of study population was 
48.3±7.5 years. The youngest patient 
was 35 years of age and the oldest was 
57 years of age. The presenting 
complaint was menometrorrhagia in 
73% (193 patients), menorrhagia in 
12.4% (32 patients), pelvic pain in 10%  
(26 patients), urinary symptoms in 3% (8 
patients), and postmenopausal 
hemorrhage in 1.6% (4 patients) of the 
patients. Patients who had not 
experienced menstruation at least for 1 
year, were deemed as menopause 
cases without checking the hormone 
profile. Thus, 85% of the study 
population (221 patients) were found to 
be premenopausal and 15% (39 
patients) were found to be 
postmenopausal patients. 
Histopathologic analysis of preoperative 
curettage specimens showed phase 
compatible endometrium in 156 (60%), 
endometrial polyp in 74 (28.5%), 
atrophic endometrium in 20 (7.7%), and 
endometrial hyperplasia in 10 (3.8%) 
patients (Graphic 1). 
 
Graphic 1.  Distribution of patients 
relative to diagnostic curettage 
results 
Among the phase compatible 
endometriums; 85 (54.5%) were 
proliferative endometrium, 39 (25%) 
were late secretory phase endometrium, 
and 32 (20.5%) were early secretory 
phase endometrium (Graphic 2). 
 
Graphic 2. Distribution of patients 
with phase compatible endometrium 
in diagnostic curettage results 
Postoperative analysis of the 
hysterectomy specimens revealed 
phase compatible endometrium in 160 
(61.5%), endometrial polyp in 61 
(23.5%), atrophic endometrium in 25 
(9.6%), and endometrial hyperplasia in 
14 (5.4%) patients (Graphic 3).   
 
Graphic 3. Distribution of patients 
relative to hysterectomy results 
Among the phase compatible 
endometriums; 96 (60%) were 
proliferative endometrium, 44 (27.5%) 
were late secretory phase endometrium, 
and 20 (12.5%) were early secretory 
phase endometrium (Graphic 4). 
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Graphic 4. Distribution of patients 
with phase compatible endometrium 
in hysterectomy results 
Comparison of the histopathologic 
results of diagnostic curettage and 
hysterectomy with regard to endometrial 
status is shown in Table 1. 
Table 1. Comparison of the 
histopathologic results of diagnostic 
curettage and hysterectomy with 
regard to endometrial status 
Pathology 
Result 
Diagnostic 
Curettage 
Result (n) 
Hysterectomy 
Result (n) 
Phase 
compatible 
endometrium 
                156                      160 
Polyp                   74                        61 
Atrophic 
endometrium 
                  20                        25 
Hyperplasia                   10                        14 
 
Histopathologic results of the diagnostic 
curettage specimens showed that 
uterine myoma and endometrial 
hyperplasia were both present in 3.8% 
of the cases (10/260), whereas 
histopathologic results of the 
hysterectomy specimens showed that 
the combination of uterine myoma + 
endometrial hyperplasia was present in 
5.3% of the patients (14/260). Accuracy 
of diagnostic curettage was 97.5% in the 
phase compatible endometrium group, 
80% in the atrophic endometrium group, 
and 71.4% in the hyperplasia group. 
The number of polyps was lower 
because of examining hysterectomy 
specimens after full curettage. In our 
study, when endometrial histopathologic 
results of diagnostic curettage and 
hysterectomy groups were compared 
relative to diagnostic accuracy, no 
statistically significant difference was 
observed (p>0.05).  
Discussion 
Besides being the most common cause 
of hysterectomy, uterine myomas are 
also the most often seen pelvic tumor in 
women.1,2 Although leiomyomas are 
encountered very rarely during the 
prepubertal age, they become 
symptomatic particularly at 30-40 year 
age group.15 In the current study, the 
mean age of patients was 48.3 ± 7.5 
years. Since we included only uterine 
myoma cases that received 
hysterectomy, the age of presentation 
was thought to be higher than the actual 
value.   
While most of the myomas are 
asymptomatic and of small size, many 
women experience serious problems 
during certain periods of their lives and 
require treatment. These symptoms vary 
depending on the number, size, 
localization, and degenerative character 
of the myomas. Abnormal uterine 
hemorrhage is the most common 
presenting symptom. The underlying 
causes of this hemorrhage are thought 
to be increased endometrial surface 
area and changes in myometrial blood 
flow associated with the stasis arising 
from compression or reduced uterine 
contractility due to presence of a mass 
leading to inadequate contraction of the 
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uterine vessels during menstruation.16 In 
the current study, the presenting 
symptom was menometrorrhagia in 73% 
(190 patients) and menorrhagia in 
12.4% (32 patients) of the patients. 
Moreover, the presenting symptom was 
pelvic pain in 10% (26 patients) of our 
patients. Myomas rarely present solely 
with pain. Large myomas may apply 
compression over the adjacent organs, 
leading to a chronic and blunt pain. In 
addition, a myoma with an intramural 
location can cause dysmenorrhea. 
Compression-related symptoms may be 
originating from a compression over the 
adjacent organs such as rectum and 
bladder. Myomas leading to 
compression over the bladder may 
cause incontinence; for example, 3% (8 
patients) of our patients had 
incontinence. 1.6% (4 patients) of our 
study population presented to our 
hospital because of postmenopausal 
hemorrhage. Those patients 
demonstrated both myoma and 
endometrial hyperplasia in the 
histopathologic analysis of curettage 
specimens.   
Many studies have shown that estrogen 
plays a role in the growth of 
leiomyomas.6  Leiomyoma cases exhibit 
increased number of estrogen receptors 
as well as elevated expression of genes 
responsible for estrogen regulators such 
as connexin 43 gap-junction protein, 
type I and 3 collagen, insulin-like growth 
factor 1, and parathyroid hormone-like 
peptide.7-11 Moreover, P450 enzyme 
system, which enables estrogen 
synthesis from androgen, also 
contributes to the growth of leiomyomas, 
and estrogen increases the mitogenic 
activity.12,13 Although uterine myomas 
develop under the influence of estrogen, 
they are not frequently seen in 
combination with endometrial 
hyperplasia or carcinomas. 
Nonetheless, although endometrial 
biopsy in patients scheduled for 
hysterectomy due to uterine myoma, is 
still a method that a majority of 
gynecologists cannot give up, the 
efficacy of diagnostic curettage in 
showing intrauterine pathologies has 
attracted more doubts.6,14,17 Epstein et 
al. found the misdiagnosis rate with 
regard to curettage findings as 58% for 
endometrial polyps, 50% for 
hyperplasias, and 11% for endometrial 
cancer.18 In the study of Hakverdi et al., 
diagnostic accuracy rate was 52% for 
atrophic endometrium, 47% for simple 
hyperplasia, 100% for atypical 
hyperplasia, 100% for adenocarcinoma, 
and 71% for phase compatible 
endometrium.19 In our study, the 
accuracy rate of diagnostic curettage 
was 97.5% for phase compatible 
endometrium, 80% for atrophic 
endometrium, and 71.4% for 
hyperplasia. Our rates were higher than 
the values reported in the literature 
which is a result that can be attributed to 
the fact that we did not separately 
analyze the subgroups of phase 
compatible endometrium and 
hyperplasia groups. 
There are many studies in the literature 
which discuss whether routinely 
applying diagnostic curettage before 
hysterectomy is necessary or not. 
Stovalt et al. note that diagnostic 
curettage is unnecessary in 
asymptomatic patients at low risk for 
malignancy, however, they also point 
out that it should be performed in cases 
above 35 years of age and showing 
abnormal uterine hemorrhage or in 
patients under 35 years of age and at 
high risk for malignancy.20 In the current 
study, 222 patients received diagnostic 
curettage because of being under 35 
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years of age and demonstrating 
abnormal uterine hemorrhage, whereas 
4 patients received diagnostic curettage 
due to presence of postmenopausal 
hemorrhage. Duplantier et al. noted that 
applying diagnostic curettage in uterine 
myoma cases showing no abnormal 
uterine hemorrhage, would be 
unnecessary, as well.21 Lerner et al. do 
not recommend diagnostic curettage in 
cases that are not thought be at high 
risk for endometrial carcinoma, and in 
their study, they found the sensitivity 
and positive predictive value of the 
procedure as 20% and 50%, 
respectively.22 In our study, no patient 
was at high risk for endometrial 
carcinoma with regard to their medical 
history, familial history, or physical and 
gynecologic examination findings. Moller 
et al. determined malignancy after 
hysterectomy in 3 (0.72%) of 411 cases 
and found that 1 of those had been 
missed by curettage, and thus they did 
not recommend diagnostic curettage.23 
In the current study, no endometrial 
malignancy was determined in our 260 
cases. In our opinion, this result can be 
associated with the low study sample.  
Conclusion 
In conclusion, we believe that routine 
diagnostic curettage is not essential with 
regard to evaluating malignancy and 
detecting a pathology that would change 
the surgery plan in uterine myoma 
cases scheduled for hysterectomy. 
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